Navigation Links
Synvista Therapeutics Posts Letter to Stockholders on Web Site
Date:9/17/2008

on track for completion in late 2009.

We have met with the FDA on these two studies and believe that our clinical endpoints are acceptable to them.

While we decided not to pursue the development of SYI-2074 in heart disease, we believe that the compound has characteristics that may make it a compelling treatment for psoriasis. We completed the formulation development for topical SYI-2074 in the third quarter of 2008, and we expect to begin patient enrollment in a 30-patient Phase 2 study in this area in October 2008.

We also have developed a new family of glutathione peroxidase mimetics with properties that may be more attractive than SYI-2074 in treating heart disease. We have selected the lead compound and have begun preclinical testing. We have shown that our new family of compounds can attenuate the loss of cholesterol efflux seen in select patients with diabetes. Higher levels of cholesterol efflux may correlate with reduced atherosclerosis.

LEADERSHIP

We welcomed several important additions to the Synvista management team in the past year. Carl Mendel, M.D., was appointed to the position of Vice President, Clinical Development and Chief Medical Officer and is responsible for the clinical-stage development of the Company's lead products. Dr. Mendel brings 15 years of experience in the pharmaceutical industry, successfully directing development programs in metabolism, obesity, cardiovascular disease, abuse potential, oncology, virology and other therapeutic areas. David C. Tantillo joined us as Senior Director, Marketing and Sales, a newly created position and brings to Synvista nearly 20 years of broad-based industry experience. Mr. Tantillo is responsible for planning and implementing commercialization of the Company's haptoglobin diagnostic test.

We strengthened our board of directors with the appointment of John F. Bedard, expanding our board to four members. Mr. Bedard brings 25 years of highly relevant experience,
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
2. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
3. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
4. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
5. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
6. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
7. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
8. Synvista Therapeutics to be Featured on Wallst.net
9. Synvista Therapeutics to Present at the BIO InvestorForum 2007
10. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
11. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Portal Solutions , a technology consulting ... Microsoft Office 365 and SharePoint platforms , today announces its ... being one of the region’s fastest-growing mid-sized companies based on ... , “To be recognized a second year in a row ...
(Date:1/22/2015)... 2015  Transwestern | RBJ today announces the firm brokered a ... Shire a leading biopharmaceutical company, at Two Ledgemont Center in ... Robert Richards , president, and Brian Cohen , senior ... five-floor building at 95 Hayden Ave. Photo - ...
(Date:1/22/2015)... Pipette.com has added the Eppendorf ... portfolio of Eppendorf products. , The Eppendorf Centrifuge 5424/5424 ... 5424/5424 R and receive the following:, , ... or Eppendorf Reference 2 ,     3 Free ...
(Date:1/22/2015)... 22, 2015 Diagenode, Inc., a ... the Bioruptor® and complete solutions for epigenetics research, ... immunoprecipitation, alleviating the need for manual processing. The ... for ChIP of histones or transcription factors and ...
Breaking Biology Technology:Washington SmartCEO Announces Portal Solutions as 2015 Future 50 Award Winner Second Year in a Row 2Washington SmartCEO Announces Portal Solutions as 2015 Future 50 Award Winner Second Year in a Row 3Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2
... Nov. 24 Boston Scientific,Corporation (NYSE: BSX ) ... which is being held December 2 - 3 in New ... will make a 30-minute presentation on,Tuesday, December 2, beginning at ... A live webcast of Mr. Tobin,s remarks will be ...
... CLAREMONT, Calif., Nov. 24 Keck Graduate Institute,s (KGI) Biotechnology ... educational event on Monday, Dec. 8, 2008. , ... (TCA), a network of individual investors who fund early-stage, technology ... of the public interested in becoming angel investors. The ...
... Omrix,s Biopharmaceutical Expertise Complements ETHICON,s Industry-Leading Surgery Portfolio ... N.J. and NEW YORK, Nov. 24 Johnson & ... Inc. (Nasdaq: OMRI ), a fully integrated ... products, today announced a definitive agreement whereby Omrix will ...
Cached Biology Technology:KGI Entrepreneur Program Hosts Angel Investing Educational Meeting 2Johnson & Johnson Announces Definitive Agreement to Acquire Omrix 2Johnson & Johnson Announces Definitive Agreement to Acquire Omrix 3Johnson & Johnson Announces Definitive Agreement to Acquire Omrix 4Johnson & Johnson Announces Definitive Agreement to Acquire Omrix 5
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has ... Market 2015-2019" report to their offering. ... trend upcoming in this market is the increasing demand ... in recording of patient data for quick and correct ...
(Date:12/11/2014)... 09, 2014 Research and Markets , ... ) has announced the addition of the "Biometrics ... One major trend emerging in this ... biometric systems utilize more than one characteristic of an ...
(Date:12/10/2014)... a leader in performance biometric data sensor technology, today ... licensees for highly accurate, clinically validated biometric technology. This ... fitness and health sectors, but first responders/military and gaming ... as useful as the biometric data it delivers. As ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... RALEIGH, NC Methyl bromide (MeBr) is a highly ... control a wide variety of pests. Under the Montreal ... of the chemicals that contributed to the depletion of ... reduction in the amount of MeBr produced and imported ...
... Progress , Burnham Institute for Medical ... and license agreement with Johnson & Johnson ... this multi-year agreement, Burnham will provide J&JPRD ... to investigate certain drug targets for inflammatory ...
... Mass., Feb. 3, 2009 -- Despite the striking aromatic ... of the nose,s neural circuitry suggests a haphazard patchwork ... likely as not to be neighbors. Inexplicably, this ... even species, with cells that process the same scent ...
Cached Biology News:Methyl bromide alternatives indicated for North Carolina tomato production 2The Burnham Buzz, February 2009 2Neural mapping paints a haphazard picture of odor receptors 2
1M stock solution (238mg/ml)...
Homogenizing Solution, 18ml Proteinase K - [50ug/l] 75 l...
Request Info...
Lipofectin Reagent is the reagent of choice for some cell lines; cells of endothelial derivation transfect well with Lipofectin Reagent....
Biology Products: